United Laboratories International Holdings Ltd 2023 SR
The report highlights The United Laboratories' 2023 ESG performance, focusing on pharmaceutical R&D, medical accessibility, and green development. Key achievements include RMB 808 million in R&D investment, 66 products in the National Medical Insurance Drug List, and a 36% reduction in non-hazardous waste per tonne of product. The company achieved zero wastewater discharge at its Inner Mongolia plant and purchased 695,461 tons of carbon quotas. Socially, it maintained a 39% female management ratio and invested RMB 3 million in stray animal protection.
Company: United Laboratories International Holdings Ltd
Sector: Health Care
Country: Hong Kong
Year: 2023
Type: SR
Pages: 126
United Laboratories International Holdings Ltd
ESG Report
The report highlights The United Laboratories' 2023 ESG performance, focusing on pharmaceutical R&D, medical accessibility, and green development. Key achievements include RMB 808 million in R&D investment, 66 products in the National Medical Insurance Drug List, and a 36% reduction in non-hazardous waste per tonne of product. The company achieved zero wastewater discharge at its Inner Mongolia plant and purchased 695,461 tons of carbon quotas. Socially, it maintained a 39% female management ratio and invested RMB 3 million in stray animal protection.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Published
Apr 15, 2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees